AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06608004 — intervention group
Intervention type: OTHER
Intervention: test taking
Description: Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
Study NCT06607068 — intervention group
Intervention type: OTHER
Intervention: None (Observational study)
Description: None (Observational study)
Study NCT06619587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Arm A
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
Study NCT06619587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Arm B
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
Study NCT06625957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTCB02-1
Description: 3 Days infusion
Study NCT06625957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTCB-C
Description: 3 Days infusion
Study NCT06630780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Head and Neck Cancers
Description: All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
Study NCT06700733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK prosthesis
Description: For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.
Study NCT06700733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium prosthesis
Description: For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.
Study NCT06715241 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination of relatlimab and nivolumab wich are two immunotherapy treatments
Description: Induction: Nivolumab 360 mg/relatlimab 360 mg fixed dose combination, IV, 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab 480 mg/relatlimab 480 mg fixed dose combination, IV 13 cycles (Q4W): 52 weeks
Study NCT06715241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nivolumab alone
Description: Induction: Nivolumab alone 360 mg, IV2 cycles (Q3W): 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab alone 480 mg, IV, 13 cycles (Q4W): 52 weeks
Study NCT06749756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B6+ Vitamin B12 +vitamin C
Description: In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
Study NCT06749756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6+ Vitamin B12
Description: In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
Study NCT06749756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C
Description: On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
Study NCT06749756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%Nacl
Description: The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
Study NCT06758037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W
Study NCT06757751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVOO diet supplement
Description: For 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil).
Study NCT06760078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid (TXA) infusion
Description: Intravenous tranexamic acid will be administered as an initial dose of 1 g (10mL: 1g, diluted in 90 mL normal saline) over 10 minutes, followed by a maintenance dose of 1 g over 8 hours (10mL: 1g, diluted in 240 mL normal saline). Intensive blood pressure lowering will be maintained throughout the treatment period until 24 hours after onset.
Study NCT06760078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
Study NCT06762431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Level 1
Study NCT06762431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Level 2
Study NCT06760676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed low dose rate radiotherapy (PLDR)
Description: Radiation 5 times per week, 2Gy each time which divided into 10 pulse doses, each pulse interval was 3 minutes, the dose rate was 0.067 Gy/min, and each treatment time was 30 minutes.
Study NCT06760676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpaloritovorelli antibodies
Description: PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.
Study NCT06761638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation Therapy
Description: Rhythmic auditory stimulation (RAS) is a therapeutic technique that uses rhythmic auditory cues, like a metronome or music, to improve motor control and coordination. It is often used in rehabilitation for conditions such as stroke, Parkinson's disease, and other movement disorders to enhance gait and other motor functions through the synchronization of movements to auditory rhythms.
Study NCT06761638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Task-Specific Training
Description: Task-specific training is a rehabilitation approach that involves practicing specific tasks or activities to improve the performance of those tasks. It is based on the principle that repetitive practice of functional tasks enhances neuroplasticity, leading to better motor skills and functional recovery, especially in stroke and neurological rehabilitation.
Study NCT06761755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hot pack , K taping , Progressive muscle relaxation
Description: Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days
Study NCT06761755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot pack , K taping , Progressive muscle relaxation
Description: Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days
Study NCT06761482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by dd-cfDNA
Description: monitoring by dd-cfDNA
Study NCT06761482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by T-Vis
Description: monitoring by T-Vis
Study NCT06761482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by dd-cfDNA+ T-Vis
Description: monitoring by dd-cfDNA+ T-Vis
Study NCT06761235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Standard BP intervention
Description: Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure.
Study NCT06761235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EVA intervention
Description: Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure. In contrast to BP arm, EVA arm will additionally reciuve counseling about vascular age.
Study NCT06761508 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention study for Arm one using video
Description: A 3 Arm randomized control trial, using video as the first Arm of intervention to assess the behaviour change of the community in hypertension prevention.
Study NCT06761508 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intervention 2:using infographics
Description: A 3 Arm randomized control trial,that involves the use of infographics in Arm to assess the behaviour change of the community in hypertension prevention.
Study NCT06761508 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intervention 3: use of pamphlet
Description: A 3 Arm randomized control trial,that contains the use of pamphlet for the 3rd Arm which is the control group to assess the behaviour change of the community in hypertension prevention.
Study NCT06761378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal stent
Description: Renal stent before flexible uretroscopy
Study NCT06761378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible uretroscopy
Description: Renal stent for 2 weeks prior flexible uretroscopy
Study NCT06762405 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: short course of radiotherapy (5 grays × 5 days)
Study NCT06762405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dostarlimab
Description: dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)
Study NCT06762405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)
Study NCT06762405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological study on circulating tumor DNA (optional for the patient)
Description: * Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses
Study NCT06762405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological study on circulating tumor DNA (optional for the patient)
Description: * Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses
Study NCT06761209 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
Study NCT06762158 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Neoadjuvant chemoradiotherapy:~1. Radiation dose: 1.8Gy/Fx, DT41.4Gy/23Fx.~2. Concurrent chemotherapy: Albumin-bound paclitaxel 60mg/m² + Cisplatin 25mg/m² on D1, D8, D15, D22, D29.
Study NCT06762158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant immunotherapy
Description: Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.
Study NCT06762158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Preoperative assessment is conducted 3 weeks after the last neoadjuvant immunotherapy, and surgery is performed within 4-6 weeks. All patients undergo minimally invasive radical esophagectomy, either McKeown or Ivor-Lewis, with extended two-field or three-field lymph node dissection.
Study NCT06762158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant immunotherapy
Description: Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
Study NCT06760949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct anterior approach hemiarthroplasty
Description: Direct anterior approach hemiarthroplasty
Study NCT06760949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lateral approach hemiarthroplasty
Description: Posterior lateral approach hemiarthroplasty
Study NCT06762587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.
Study NCT06762587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be administered once daily for 5 consecutive days following the close contact's enrollment in this study. Participants will receive 75 mg of oseltamivir once each day.
Study NCT06762197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.
Study NCT06762197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.
Study NCT06762197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: Shockwave therapy is a non-invasive alternative treatment for muscle disorders like sports and traumatic injuries, as it reduces pain and promotes soft tissue repair. In a study, patients in group A were treated with three sessions of Storz Medical Shock Wave MP100, each consisting of 2000 pulses with a total energy dose of 1080 mJ / mm. The study aimed to determine the location of the piriformis muscle in the prone position.
Study NCT06762197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Low Level Laser Therapy, also known as Photo-biomodulation, is a low-intensity light therapy that triggers biochemical changes within cells, similar to photosynthesis in plants. It can treat nociceptive and neuropathic pain, but central pain has not been proven responsive to low level laser therapy.
Study NCT06761547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnsium sulfate
Description: patients will take magnsium sulfate 15 mg/kg IV
Study NCT06761547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: patients will take lidocaine2% 1 mg/kg
Study NCT06761547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 50 ml saline IV
Study NCT06761547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 50 ml saline IV
Study NCT06761053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention/Exposure for the GDM Group (Experimental Arm)
Description: Gestational Diabetes Diagnosis: The intervention for this group involves the diagnostic procedure of the 100-gram oral glucose tolerance test (OGTT) after an initial glucose challenge test (GCT) with a result equal to or greater than 140 mg/dL. The test assesses fasting plasma glucose and post-glucose consumption plasma glucose levels at 1 hour and 2 hours, which is used to diagnose GDM.~Biomarker Analysis: The albumin to high-sensitivity C-reactive protein (hsCRP) ratio is measured as a biomarker to explore its potential role in GDM diagnosis and related pregnancy outcomes.
Study NCT06761053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Intervention/Exposure for the Control Group
Description: Glucose Challenge Test (GCT): The control group participants are exposed to the glucose challenge test (GCT), where plasma glucose levels are measured one hour after the consumption of 50 grams of glucose. If their glucose levels are below 140 mg/dL, they are categorized as not having GDM.~Biomarker Analysis: Similar to the GDM group, the albumin to hsCRP ratio is measured for participants in the control group to compare the biomarker levels between those with and without GDM.
Study NCT06761274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral blood sampling
Description: It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:~* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).~* newly diagnosed (stage II b, III or IV, Ann Arbor Classification).
Study NCT06761950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level laser therapy
Description: The patient received low-level laser therapy three times per week for four weeks, with immobilization maintained. The Mustang 2000 Laser device was used with an infrared laser probe to accelerate tendon healing. The device's specifications include peak power output of 15W, power density of 15W/cm2, wave length of 890nm, pulse frequency of 100Hz, spherical size of 0.002cm2, pulse duration of 130 ns, exposure duration of 60 sec, and energy density of 5.85J/cm2.
Study NCT06761950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo low level laser therapy
Description: Same as in the study group except turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect 3 sessions per week for 4 weeks.
Study NCT06761950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical treatment
Description: the patients received their drugs from their treating physicians
Study NCT06761950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: the patients received their drugs from their treating physicians
Study NCT06761950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program
Description: patients received the traditional program after flexor tendon repair involving isometric exercise, stretching and mobilizations
Study NCT06761950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy program
Description: patients received the traditional program after flexor tendon repair involving isometric exercise, stretching and mobilizations